GLP-1 Evidence

Użi oħra

Mediċini GLP-1: riżultati fuq reni, fejqan, u apnoea

Xi wħud mill-iskoperti mhux relatati mal-piż huma daqshekk sodisfaċenti bħad-dejta tal-piż. Oħrajn huma prova żgħira waħda u ħafna entużjażmu. Hawnhekk huwa liema huwa liema.

Aġġornat 3 min read 24 ċitazzjonijiet Saħħa tal-evidenza 3/5

Bank ta' laboratorju tal-kimika bi fliexken tal-ħġieġ u boroż ta' reattivi f'pożizzjoni
Cjp24 · CC BY-SA 3.0 · Wikimedia Commons

Reni: l-aktar każ b'saħħtu mhux relatat mal-piż

Meta-analiżi tal-2025 ta' provi randomizzati eżaminat ir-riżultati tar-reni u tal-mard kardjovaskulari flimkien u sab vantaġġ konsistenti [1]. F'nies li diġà għandhom mard kroniku tar-reni, reviżjoni sistematika fokusa waslet għall-istess konklużjoni [2]. Analiżi preċedenti diġà kienet indikat is-sinjal tar-reni flimkien mal-kardjovaskulari [5][10], u tirzepatide wera vantaġġ tar-reni kontra l-insulin glargine fl-analiżi SURPASS-4 [7].

Il-relazzjoni bejn l-obesità u l-mard tar-reni hija stess karatterizzata tajjeb [9], għalhekk triq medjata mill-piż hija plawżibbli — iżda bħalma jiġri mal-riżultati kardjovaskulari, il-provi ma jistgħux isibu separazzjoni bejn effetti diretti u effetti medjati mill-piż.

Vantaġġ tar-riżultati tar-reni

Fejqan: fil-linji gwida

Il-mard tal-fwied assoċjat mad-dysfunzjoni metabolika huwa l-qasam fejn l-użu mhux relatat mal-piż ħa l-aktar passi mgħaġġla minn prova għal prattika. Tirzepatide naqqas il-kontenut tal-fatt tal-fwied u t-tessut adipuż abdominali kontra l-insulin degludec f'komparazzjoni randomizzata [6], u semaglutide akkumula biżżejjed evidenza biex jinstab fil-linji gwida formali Ewropej. Meta-analiżi tan-netwerk ta' trattamenti ta' mediċini tad-dijabete poġġi din il-klassi f'pożizzjoni favorevoli fuq il-bilanċ ġenerali ta' vantaġġi u ħsara [4].

Tnaqqis fil-fatt tal-fwied

Apnoea tal-ħolqien

Kopert b'mod sħiħ fuq il-paġna ta' tirzepatide: prova randomizzata ddedikata f'apnoea tal-ħolqien moderata sa severa b'obesità pproduċiet tnaqqis sostanzjali fl-indice ta' apnoea-hypopnoea. Dan huwa l-ewwel mediċina b'evidenza randomizzata f'kundizzjoni li sa issa kienet esklussivament id-dominju ta' CPAP u kirurġija.

Dipendenza: l-iktar waħda interessanti, u l-aktar fqira

Il-kwistjoni mekkanika hija attraenti. Ir-riċetturi GLP-1 huma preżenti fil-kirku tar-rikonoxximent tal-moħħ, il-mediċini jnaqqsu l-ħtieġa relatata mal-ikel, u l-utenti rapportaw spontanjament li jixorbu inqas alkoħol. Jekk is-sinjalizzazzjoni GLP-1 timmodifika r-rikonoxximent ġeneralment minflok ir-rikonoxximent tal-ikel speċifikament, l-effetti fuq mġiba oħra ta' dipendenza jsegwu.

L-evidenza umana ma ħarġitx 'il quddiem. Prova randomizzata kontrollata bil-placebo ta' exenatide f'mard tal-użu tal-alkoħol ma pproduċietx riżultat pożittiv ċar primarju, għalkemm rapportat sinjali f'subgruppi u punti ta' imaging [8]. Dan huwa bażi raġonevoli għal provi ulterjuri u bażi fqira għal preskrizzjoni.

Dipendenza u użu ta' sustanzi

Dak li aħna m'għandniex intenzjoni li nkopru għad

Neurodegenerazzjoni, sindromu tal-ovarji polikistiċi, infjammazzjoni kronika u riskju ta' kanċer kollha għandhom programmi attivi ta' prova u kważi l-ebda evidenza randomizzata kompluta fil-popolazzjonijiet li qed jiġu diskussi online. Meta dawn il-provi jirrapurtaw, din il-paġna tibdel. Sa dakinhar, it-trattament tagħhom bħala stabbilit huwa eżatt l-iżball li jagħmel il-kittieb tas-saħħa inaffidabbli.

Mistoqsijiet komuni

Se tgħinni bix-xorb tiegħi?
Possibilment, imma l-prova rrandomizzata waħda ma wrietx benefiċċju ċar fuq il-punt finali primarju tagħha [8]. L-anekdota bħalissa qed tiġi qabel l-evidenza.
Nista' nieħdu għall-protezzjoni tal-kliewi?
L-evidenza dwar il-kliewi hija b'saħħitha [1][2] u dan qed isir dejjem aktar parti mill-gwida klinika fid-dijabete u l-mard kroniku tal-kliewi. Hija konversazzjoni li għandek ikollok ma' nefrologu.
Inaqqas l-infjammazzjoni?
Il-markaturi infjammatorji jitjiebu, imma dan huwa mistenni b'telf ta' piż sostanzjali u ma jistabbilixxix waħdu benefiċċju kliniku.
Hija utli għas-sindromu tal-ovarji poliċistiċi (PCOS)?
It-telf tal-piż jgħin lis-sindromu tal-ovarji poliċistiċi, u dawn il-mediċini jikkawżaw telf ta' piż. L-evidenza rrandomizzata dedikata b'punti finali speċifiċi għall-PCOS hija limitata.
Pinna tal-injezzjoni tal-insulina mmarkata tul tulha kontra sfond isfar
Wesalius · CC BY 4.0 · Wikimedia Commons

Qari relatat

Il-provi li hemm wara din il-paġna Bar imwaħħal li juri l-kompożizzjoni tal-12 pubblikazzjoni ċċitata f'din il-paġna skont it-tip ta' studju. 6411meta-analysis (6)randomised trial (4)review (1)other (1)
12 pubblikazzjonijiet, 2019–2025. Dan huwa ammont li jinkludi kemm provi kif ukoll sinteżi, li huwa l-pożizzjoni minn fejn talba dwar il-kawża hija raġonevoli. Sors: il-lista ta' ċitazzjonijiet ta' din il-paġna, hawn taħt.

Referenzi

Kull ċitazzjoni hawn taħt tgħaqqad mal-record oriġinali peer-reviewed fuq PubMed jew permezz ta' DOI. Xejn hawnhekk m'għandux ikun sostitut għal parir mediku.

  1. Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis Peng TR, Lin HH, Tseng TL, et al. · British journal of clinical pharmacology · 2026 · Meta-analysis DOIPubMed 42273973Full text
  2. Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis AbdelMagid AM, Kamel AM, Farid SF · Pharmacotherapy · 2026 · Meta-analysis DOIPubMed 41947610
  3. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  4. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis Elganyny MKE, Elganyni AKE, Maskji HA, et al. · La Clinica terapeutica · 2026 · Meta-analysis DOIPubMed 42340790
  5. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  6. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  7. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  8. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  9. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  10. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  11. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  12. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  13. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  14. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight Malhotra A, Grunstein RR, Azarbarzin A, et al. · Sleep medicine · 2025 · Randomised controlled trial DOIPubMed 41135142Full text
  15. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) Agarwal R, Green JB, Heerspink HJL, et al. · Diabetes care · 2025 · Randomised controlled trial DOIPubMed 40968755Full text
  16. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  17. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  18. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  19. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes] Scheen AJ, Radermecker RP, Paquot N · Revue medicale suisse · 2022 · Randomised controlled trial DOIPubMed 36004653
  20. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  21. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes care · 2020 · Randomised controlled trial DOIPubMed 32291277Full text
  22. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Van Kleef LA, Michel M, Alkhouri N, et al. · Drug design, development and therapy · 2026 · Review DOIPubMed 41868171Full text
  23. Chronic Kidney Disease and Obesity Hojs R, Ekart R, Bevc S, et al. · Nephron · 2023 · Review DOIPubMed 37271131
  24. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083

Din il-paġna ġiet tradotta awtomatikament mill-Ingliż. Il-citazzjonijiet u n-numri mhumiex mibdula. Aqra l-original Ingliż jekk xi ħaġa taqra b'mod stramb. Aqra l-original Ingliż